Avicenna Alliance

Tweet this page
<
2021
2022
2023
>
No longer registered as of 14 Mar 2024 - Registration as it was on 08 Mar 2023
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

50,000€ - 99,999€

Financial year: Jan 2022 - Dec 2022

Lobbyists (Full time equivalent)

1.25 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Avicenna Alliance

    EU Transparency Register

    217362043770-33 First registered on 12 Aug 2021

    Goals / Remit

    The Avicenna Alliance is a global non-profit organization advocating for the adoption and regulation of Computer Model and Simulation (CM&S, also known as In Silico medicine). The Alliance brings together health care stakeholders with the goal of making in silico medicine a standard practice in health care through a collaborative ecosystem of patients, clinicians, academics, industries, policymakers, regulators & payers.

    Its objectives include:

    •Ensure a policy framework to facilitate the large-scale development and acceptance of in silico medicine
    •Bridge the gap between basic research and the commercialisation of products by exploring areas of mutual cooperation and benefit
    •Significantly reduce time and costs of approval and reimbursement processes for healthcare technologies to foster medical innovation
    •Pave the way towards the development, regulation and largescale adoption of Digital Twin and Personal Digital Avatars

    Main EU files targeted

    • Proposal for a regulation on a European Health Data Space
    • Europe’s Beating Cancer Plan
    • Regulation on a European approach for Artificial Intelligence
    • New Coordinated Plan on Artificial Intelligence
    • Proposal for a regulation on the European Health Emergency Preparedness and Response Authority (HERA)
    • Regulation on serious cross-border threats to health
    • Proposal for a Regulation on a reinforced role of the EMA
    • Council Regulation on establishing the new European High-Performance Computing Joint Undertaking
    • Pharmaceutical Strategy
    - Revision of EU rules on medicines for children and rare diseases
    - Revision of the EU general pharmaceuticals legislation

    Address

    Head Office
    Rue Guimard 10
    Brussels 1040
    BELGIUM
    EU Office
    Rue Guimard 10
    Brussels 1040
    BELGIUM

    Website

  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    50%2
    25%1

    Lobbyists (Full time equivalent)

    1.25

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 04 May 2024

    Name Start date End Date
    Thierry MARCHAL 10 Mar 2023 11 Mar 2024

    Complementary Information

    /

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    /

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2022 - Dec 2022

    Lobbying costs for closed financial year

    50,000€ - 99,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    rpp group 50,000€ - 99,999€

    Intermediaries for current year

    Name
    rpp group

    Closed year Costs

    50,000€ - 99,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    eHealth Stakeholder Group#E02769#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupID=2769 #Member #C#Industry, Academia/Research, SMEs

    Groups (European Parliament)

    N/A

    Communication activities

    The Alliance analyses, monitors and engages with multiple topics in EU policy, among which medical devices, artificial intelligence, health data and pharmaceuticals through various activities:

    • Development of position papers and white papers
    • Publishing of case studies
    • Providing feedback to EU public consultations
    • Organisation of events and workshops, generally targeted at policymakers for the purpose of calling to action and/or informative purposes
    • Political engagement with Members of the European Parliament, European Commission and Council representatives

    Other activities

    Ehealth stakeholder group

  • Meetings

    Meetings

    None declared

Download this datacard